The KromaTiD dGH gene tracking platform combines a chromatid paint (or smaller subset of probes) labeled with one fluorophore, and gene-specific probes labeled with a contrasting fluorophore in a single multiplex assay.  The different fluorescent tags enable a gene of interest to be ‘tracked’ in the context of surrounding genomic sequences. Based on Directional Genomic Hybridization (dGH) technology, gene tracking probes hybridize to just one chromatid, making it easy to visualize structural rearrangements -including translocations, deletions and previously difficult to detect inversions-in the target gene. Since gene tracking assays generate data for single cells, not pools of cells, they are ideal for mixed cell population studies. Benefits include:

  • Detection of Structural Rearrangements in Cell Populations: Gene tracking assays are capable of detecting structural rearrangements within a gene; they are ideal both for confirming known rearrangements and for discovering new ones. In an unstable population of cells, such as within a tumor, gene tracking assays can easily characterize different rearrangements.
  • Customizable for Specific Research Needs: Gene tracking assays are available for most genes in the human genome and any previously-sequenced mammalian genome. Assay components and protocols are completely customized to fit client research needs.
  • Rapid Development and Delivery: Custom dGH gene tracking assays are available in 50-assay kits. Unlike other chromosome imaging technology made-to-order assays that take months to develop, KromaTiD can generate a personalized gene tracking assay within a matter of weeks.